Abstract 472: Prevalence of Fredrickson-Levy Dyslipidemia Phenotypes at Extreme HDL-C Levels: The Very Large Database of Lipids (VLDL-9B)
Introduction: Big data techniques offer a novel opportunity to characterize individuals with extreme phenotypes. In this context, we aimed to describe the prevalence of classical Fredrickson-Levy dyslipidemia phenotypes at the extremes of HDL-C levels in a cross-sectional big data study.
Methods: We examined 848,801 U.S. adults and children from the Very Large Database of Lipids 1.0 who were referred for lipoprotein testing from 2009 to 2011. We categorized patients into HDL-C percentile categories (<0.1th, 0.1th to 99th to 99.9th, and >99.9th). We examined the prevalence of Fredrickson-Levy dyslipidemia phenotypes (I, IIa, IIb, III, IV and V) within these categories. We identified those who did not meet criteria for any classical dyslipidemia phenotype as the continuum group.
Results: Type I and V were mostly present at extremely low HDL-C levels. Type IIa was more prevalent in high vs. low HDL-C levels. Type III was 2-fold more prevalent in extremely low vs. high HDL-C levels. Type IV was the most prevalent classical dyslipidemia phenotype in our population, and was the most frequent at low HDL-C percentiles. About 50% of the extremely low and 90% of the extremely high HDL-C levels were classified into the continuum group.
Conclusion: In our cross-sectional big data analysis, there was a significantly higher prevalence of most classical dyslipidemia phenotypes at extremely low HDL-C compared with extremely high HDL-C levels. Only types I and V were more prevalent in extreme groups than general population. To some extent, very low HDL-C levels may be determined by inheritable, highly atherogenic dyslipidemias.
Author Disclosures: R. Quispe: None. M. Al-Hijji: None. K.J. Swiger: None. S.S. Martin: None. M. Elshazly: None. M.J. Blaha: Consultant/Advisory Board; Modest; Pfeizer. P.H. Joshi: None. R.S. Blumenthal: None. A. Sniderman: None. P.P. Toth: Speakers Bureau; Modest; Amarin, Amgen, AstraZeneca, Genzyme, Kowa, Merck. Consultant/Advisory Board; Modest; Amgen, AstraZeneca, Atherotech, GlaxoSmithKline, Kowa, Liposcience, and Merck. S.R. Jones: Consultant/Advisory Board; Modest; Atherotech.
- © 2015 by American Heart Association, Inc.